- Record: found
- Abstract: not found
- Article: not found
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam ,
Randy F. Sweis ,
F. Stephen Hodi ,
Wells A. Messersmith ,
Robert H.I. Andtbacka ,
Matthew Ingham ,
Nancy Lewis ,
Xinhui Chen ,
Marc Pelletier ,
Xueying Chen ,
Jincheng Wu ,
Sarah M. McWhirter ,
Thomas Müller ,
Nitya Nair ,
Jason J. Luke
October 29 2021
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of MIW815
(ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of
IFN genes (STING) pathway, in patients with advanced/metastatic cancers.
Related collections
Author and article information
Comments
Comment on this article
scite_
0
0
0
0
Smart Citations0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.